-
Hapoaliom Views Arena's Lorcaserin As Unapprovable
Thursday, December 23, 2010 - 10:12am | 233Hapoalim Securities has published a research report on Arena Pharmaceuticals (NASDAQ: ARNA) after the company completed its End of Review meeting with the FDA concerning Lorcaserin. In the report, Hapoalim Securities writes "Arena announced that it has completed the planned Type A (End of Review)...
-
Label Expansion Sought for Byetta - Analyst Blog
Thursday, December 23, 2010 - 10:03am | 599Amylin Pharmaceuticals, Inc. (AMLN) and partner Eli Lilly and Company (LLY) recently submitted a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) seeking a label expansion for their type II diabetes drug, Byetta. The companies are looking to get Byetta...
-
Benzinga's Top Pre-Market NASDAQ Gainers (SNIC, VRGY, SQNM, AIXG)
Thursday, December 23, 2010 - 9:18am | 152Sonic Solutions (NASDAQ: SNIC) rose 24.94% to $14 in the pre-market session. Rovi Corp (NASDAQ: ROVI) announced its plans to acquire SNIC for about $720 million. Verigy Ltd (NASDAQ: VRGY) added 9.98% to $13.89 in pre-market trading. Advantest Corp (NYSE: ATE) raised its unsolicited buyout offer for...
-
Label Expansion Sought for Byetta - Analyst Blog
Thursday, December 23, 2010 - 9:15am | 599Amylin Pharmaceuticals, Inc. (AMLN) and partner Eli Lilly and Company (LLY) recently submitted a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) seeking a label expansion for their type II diabetes drug, Byetta. The companies are looking to get Byetta...
-
Piper Jaffray Maintains Overweight On Sequenom (SQNM)
Thursday, December 23, 2010 - 8:27am | 161Piper Jaffray is maintaining its Overweight rating on Sequenom Inc. (NASDAQ: SQNM). It has a $8 price target. In a note sent to clients, Piper Jaffray writes, "Sequenom announced the commencement of the Trisomy 21 (T21) pivotal clinical validation study, in line with our timeline expectations....
-
Bioanalytical Systems, Inc. Reports Q4FY10 Revenue of $7.4
Wednesday, December 22, 2010 - 5:33pm | 94BASi (Bioanalytical Systems, Inc.) (NASDAQ: BASI) today reported financial results for the three and twelve months ended September 30, 2010. Revenue decreased 13.1% in the fourth quarter of fiscal 2010 to $7.4 million compared to revenue of $8.5 million for the same period in fiscal 2009. Service...
-
Arrowhead Reports Revenue of $181k
Wednesday, December 22, 2010 - 5:03pm | 110Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2010 fourth quarter and year ended September 30, 2010. For the quarter ended September 30, 2010, Arrowhead's revenue was $181,000, compared with $187,000 in the quarter ended September 30, 2009. Total...
-
Another Setback for AstraZeneca - Analyst Blog
Wednesday, December 22, 2010 - 10:03am | 679AstraZeneca (AZN) suffered another pipeline setback recently with the company announcing that it no longer intends to develop motavizumab for the prophylaxis of serious respiratory syncytial virus (RSV) disease. The company has requested the US Food and Drug Administration (FDA) to withdraw the...
-
Another Setback for AstraZeneca - Analyst Blog
Wednesday, December 22, 2010 - 9:15am | 679AstraZeneca (AZN) suffered another pipeline setback recently with the company announcing that it no longer intends to develop motavizumab for the prophylaxis of serious respiratory syncytial virus (RSV) disease. The company has requested the US Food and Drug Administration (FDA) to withdraw the...
-
Arena Pharmaceuticals Set To Reopen 8:15am After FDA End-Of-Review (ARNA)
Wednesday, December 22, 2010 - 9:13am | 235Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) is currently halted, but shares are scheduled to resume trading by NASDAQ at 8:15am. Shares last traded this morning at $2.17. Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today the completion of an end-of-review meeting with the US...
-
Architecture Billings Index Hits Pre-Recession Level
Wednesday, December 22, 2010 - 8:51am | 303Washington, D.C. (link will appear shortly) – "After stepping back in October reversing into the negative territory, the Architecture Billings Index (ABI) rose more than three points in November to reach its highest mark since December 2007. As a leading economic indicator of construction...
-
Bruker Announces Acquisition of Sigma ElectroOptics GmbH
Tuesday, December 21, 2010 - 10:26am | 62Bruker (NASDAQ: BRKR) today announced the signing of an agreement with simultaneous closing of the acquisition of Sigma ElectroOptics GmbH. Sigma's 2010 revenue is expected to be about one million Euro. Financial details of the transaction were not disclosed. Sigma will be integrated into the...
-
King Pharma Files NDA for Pain Drug - Analyst Blog
Tuesday, December 21, 2010 - 10:03am | 446King Pharmaceuticals, Inc. (KG) and partner Acura Pharmaceuticals, Inc. (ACUR) recently announced the submission of a new drug application (NDA) for their opioid candidate, Acurox. The companies are seeking US Food and Drug Administration (FDA) approval for the use of Acurox (without niacin) for...
-
Zacks #1 Rank Additions for Tuesday - Tale of the Tape
Tuesday, December 21, 2010 - 9:33am | 339Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: 51job Inc (JOBS) Aar Corp (AIR) Banco Bradesco (BBD) Buckeye Tech (BKI) Caliper Life Sciences (CALP) View the entire Zacks #1 Rank List. AAR CORP (AIR): Free Stock Analysis Report BANCO BRADESCO (BBD): Free Stock Analysis...
-
King Pharma Files NDA for Pain Drug - Analyst Blog
Tuesday, December 21, 2010 - 9:30am | 446King Pharmaceuticals, Inc. (KG) and partner Acura Pharmaceuticals, Inc. (ACUR) recently announced the submission of a new drug application (NDA) for their opioid candidate, Acurox. The companies are seeking US Food and Drug Administration (FDA) approval for the use of Acurox (without niacin) for...